^
No biomarker
Burkitt Lymphoma
cyclophosphamide intravenous
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
CODOX-M + rituximab
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
R-CVAD
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
R-CVAD + cytarabine + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
EPOCH-R + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RGDP
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RICE
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RIVAC + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RIVAC
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RICE + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
rituximab + cytarabine
Sensitive
:
A2
LDH elevation
Burkitt Lymphoma
ViPOR
Sensitive
:
C3
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone
Sensitive
:
C4
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
idelalisib
Sensitive
:
C4
TP53 A159V
Burkitt Lymphoma
PZ01
Sensitive
:
C4
CD19 positive + CD20 positive
Burkitt Lymphoma
rituximab + FT596
Sensitive
:
D
LY9 expression
Burkitt Lymphoma
T-lymphocyte cell therapy
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our